Related Experiment Video
Updated: Jun 9, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Front-line management of diffuse large B cell lymphoma
1Department of Medicine, University of Puerto Rico School of Medicine, Centro de Cancer, Auxilio Mutuo, San Juan, Puerto Rico. fcabanil@mdanderson.org
Current Opinion in Oncology
|September 3, 2010
Summary
Modern diffuse large B cell lymphoma treatments, including rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), have significantly improved cure rates. Dose-dense regimens show promise, but further research is needed for consensus.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Diffuse large B cell lymphoma (DLBCL) management has seen significant progress.
- Modern treatment regimens have increased cure rates from 40% to approximately 75%.
Purpose of the Study:
- To review recent advances in DLBCL treatment.
- To highlight areas of consensus and controversy in DLBCL management.
Main Methods:
- Review of clinical data and treatment regimens for DLBCL.
- Comparison of standard CHOP regimen with rituximab-enhanced regimens (R-CHOP) and dose-dense variations (CHOP-14).
Main Results:
- The R-CHOP regimen significantly improves survival compared to CHOP alone.
- Dose-dense CHOP-14 demonstrates superiority over standard CHOP given every 21 days.
Conclusions:
- Consensus exists on using R-CHOP as front-line treatment for DLBCL.
- Maintenance rituximab is not effective for DLBCL, unlike in follicular lymphomas.
- Head-to-head comparison of R-CHOP-14 and R-CHOP-21 is lacking, preventing consensus on the former's superiority.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:15Secondary Lymphoid Organs
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...